Integrating ancillary studies in a large clinical trial: The design and rationale of the APEX library

Contemporary Clinical Trials

Volumn 29, Issue 6, 2008, Pages 887-895

  Mahaffey, Kenneth W ^a   Reist, Craig J ^a   Fu, Yuling ^b   Brener, Sorin J ^c   Theroux, Pierre ^d   Patel, Manesh R ^a   Stebbins, Amanda ^a   Westerhout, Cynthia M ^b   Todaro, Thomas G ^e   Adams, Peter X ^f   Granger, Christopher B ^a   Armstrong, Paul W ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c LERNER RESEARCH INSTITUTE   (United States)

^d MONTREAL HEART INSTITUTE   (Canada)

^e PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^f ALEXION PHARMACEUTICALS   (United States)

Author keywords

Clinical trials; Library substudy

Indexed keywords

BIOLOGICAL MARKER;

ACUTE HEART INFARCTION; ANGIOGRAPHY; ARTICLE; CLINICAL TRIAL; DEMOGRAPHY; ELECTROCARDIOGRAM; GENETICS; INFLAMMATION; INFORMATION PROCESSING; LIBRARY SCIENCE; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATIENT CARE; PATIENT SELECTION; THROMBOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; CORONARY THROMBOSIS; DOUBLE-BLIND METHOD; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MULTICENTER STUDIES AS TOPIC; MYOCARDIAL REPERFUSION; RESEARCH DESIGN;

EID: 53649094569     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2008.06.003     Document Type: Article

References (14)

1. Ross A.M., Coyne K.S., Moreyra E., et al. Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. Circulation 97 (1998) 1549-1556
2. Ohman E.M., Armstrong P.W., Christenson R.H., et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 335 (1996) 1333-1341
3. Newby L.K., Ohman E.M., Christenson R.H., et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. Circulation 103 (2001) 2891-2896
4. Petersen J.L., Mahaffey K.W., Becker R.C., et al. Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library. Am Heart J 148 (2004) 269-276
5. APEX AMI Investigators. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 297 (2007) 43-51
6. Armstrong P.W., Adams P.X., Al-Khalidi H.R., et al. Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J (2005) 402-407
7. Armstrong P.W., and Granger C.B. Reflections on early stopping of a clinical trial. Am Heart J 152 (2006) 407-409
8. Schroder R., Wegscheider K., Schroder K., Dissmann R., and Meyer-Sabellek W. for the INJECT Trial Group. Extent of early ST-segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial. J Am Coll Cardiol 26 (1995) 1657-1664
9. Armstrong P.W., Wagner G., Goodman S.G., et al. ST-segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction. Eur Heart J 24 (2003) 1515-1522
10. Fu Y., Goodman S., Chang W.C., Van de Werf F., Granger C.B., and Armstrong P.W. for the ASSENT 2 Investigators. Time to treatment influences the impact of ST-segment resolution on one-year prognosis: insights from ASSENT 2. Circulation 104 (2001) 2653-2659
11. Hindman N.B., Schocken D.D., Widmann M., et al. Evaluation of a QRS scoring system for estimating myocardial infarct size. V specificity and method of application of the complete system. Am J Cardiol 55 (1985) 1485-1490
12. Wagner G.S., Freye C.J., Palmeri S.T., et al. Evaluation of a QRS scoring system for estimating myocardial infarct size. I specificity and observer agreement. Circulation 65 (1982) 342-347
13. Granger C.B., Mahaffey K.W., Weaver W.D., et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 108 (2003) 1184-1190
14. Theroux P., Armstrong P.W., Mahaffey K.W., et al. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur Heart J 26 (2005) 1964-1970